The combined safety results of two studies with the atezolizumab plus bevacizumab combination were presented at the European Society of Medical Oncology (ESMO) Congress in Munich, Germany last week.
The phase 2 IMmotion 150 clinical trial compared the efficacy of the atezolizumab plus bevacizumab combination with atezolizumab alone and sunitinib alone, and then allowed for crossover to the combination arm. The phase 3 IMmotion 151 trial compared the efficacy of the atezolizumab plus bevacizumab combination with sunitinib for first-line treatment of metastatic renal cell carcinoma (RCC). These two studies suggest that atezolizumab plus bevacizumab may be a reasonable first-line treatment in select patients with advanced RCC, with 32% response rates (46% in PD-L1 positive patients) and progression-free survival of 11.7 months versus 8.4 months for sunitinib (IMmotion 150, not statistically significant).
The combined safety results from IMmotion 150 and IMmotion 151 demonstrate that the atezolizumab plus bevacizumab combination has a safety profile comparable to sunitinib, is tolerated by most patients, and may be a reasonable first-line treatment option for people with metastatic RCC.